Qualigen Therapeutics Inc (QLGN)

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 8-K - Current report

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

Shareholders approved all proposals, confirming Faraday Future Intelligent Electric Inc. (“Faraday Future”) as...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025

Dubai, UAE / Beijing, China, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN...

Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation

New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) (“Qualigen”, “QLGN”...

Form DEF 14A - Other definitive proxy statements

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”...

Form PRE 14A - Other preliminary proxy statements

Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition

Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”...

Form 8-K - Current report